Biologics have emerged as frontline medicines to combat a number of conditions. However, despite some successes, a number of these therapeutic approaches, such as CAR-T’s, have taken a very long time to develop. Other approaches, such as the recently withdrawn from market ADC, Mylotarg, have led to unexpected failures. Meanwhile approaches such as antibody-dependent pro-drug therapy (ADEPT) and targeted biologic toxins (e.g. pseudomonas exotoxin) seemed like good ideas, but failed to progress in spite of years of testing.
The goal of this session is to understand quantitative issues around successes and failures of multi-component biological drugs. Here, we will explore the novel quantitative design challenges around such new therapies to answer:
Workshop Leader: Jeffrey Way, Senior Staff Scientist, Wyss Institute, Harvard University